Literature DB >> 22583457

Comparison of 7-day recall and daily diary reports of COPD symptoms and impacts.

Antonia V Bennett1, Dagmar Amtmann, Paula Diehr, Donald L Patrick.   

Abstract

OBJECTIVE: Patient reporting of symptoms in a questionnaire with a 7-day recall period was expected to differ from symptom reporting in a 7-day symptom diary on the basis of cognitive theory of memory processes and several studies of symptoms and health behaviors.
METHODS: A total of 101 adults with chronic obstructive pulmonary disease (COPD) completed a daily diary of items measuring symptoms and impacts of COPD for 7 days, and on the seventh day they completed a questionnaire of the same items with a 7-day recall period. The analysis examined concordance of 7-day recall with summary descriptors of the daily responses, examined the magnitude and covariates (patient characteristics and response patterns) of the difference between 7-day recall and mean of daily responses, and compared the discriminant ability and ability to detect change of 7-day recall and mean of daily responses.
RESULTS: A 7-day recall was moderately concordant with the mean and maximum of daily responses and was 0.34 to 0.50 SDs higher than the mean of daily responses. Only the weekly report itself was a covariate of the difference. The discriminant ability and ability to detect change were equivalent.
CONCLUSIONS: In measuring the weeklong experience of COPD symptoms and impacts on groups of patients, the 7-day recall scores were higher than the daily diary scores, but equivalent in detecting change over time.
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22583457     DOI: 10.1016/j.jval.2011.12.005

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  14 in total

1.  Detecting COPD exacerbations early using daily telemonitoring of symptoms and k-means clustering: a pilot study.

Authors:  Daniel Sanchez-Morillo; Miguel Angel Fernandez-Granero; Antonio León Jiménez
Journal:  Med Biol Eng Comput       Date:  2015-03-01       Impact factor: 2.602

2.  Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Authors:  Ethan Basch; Bryce B Reeve; Sandra A Mitchell; Steven B Clauser; Lori M Minasian; Amylou C Dueck; Tito R Mendoza; Jennifer Hay; Thomas M Atkinson; Amy P Abernethy; Deborah W Bruner; Charles S Cleeland; Jeff A Sloan; Ram Chilukuri; Paul Baumgartner; Andrea Denicoff; Diane St Germain; Ann M O'Mara; Alice Chen; Joseph Kelaghan; Antonia V Bennett; Laura Sit; Lauren Rogak; Allison Barz; Diane B Paul; Deborah Schrag
Journal:  J Natl Cancer Inst       Date:  2014-09-29       Impact factor: 13.506

3.  Comparison of seven-day and repeated 24-hour recall of symptoms in the first 100 days after hematopoietic cell transplantation.

Authors:  William A Wood; Allison M Deal; Antonia V Bennett; Sandra A Mitchell; Amy P Abernethy; Ethan Basch; Charlotte Bailey; Bryce B Reeve
Journal:  J Pain Symptom Manage       Date:  2014-08-13       Impact factor: 3.612

4.  Concept domain validation and item generation for the Treatment-Induced Neuropathy Assessment Scale (TNAS).

Authors:  Loretta A Williams; Araceli Garcia-Gonzalez; Tito R Mendoza; Shireen Haq; Charles S Cleeland
Journal:  Support Care Cancer       Date:  2018-08-10       Impact factor: 3.603

Review 5.  Ambulatory and diary methods can facilitate the measurement of patient-reported outcomes.

Authors:  Stefan Schneider; Arthur A Stone
Journal:  Qual Life Res       Date:  2015-06-23       Impact factor: 4.147

6.  Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.

Authors:  Tito R Mendoza; Amylou C Dueck; Antonia V Bennett; Sandra A Mitchell; Bryce B Reeve; Thomas M Atkinson; Yuelin Li; Kathleen M Castro; Andrea Denicoff; Lauren J Rogak; Richard L Piekarz; Charles S Cleeland; Jeff A Sloan; Deborah Schrag; Ethan Basch
Journal:  Clin Trials       Date:  2017-03-20       Impact factor: 2.486

7.  Measurement of Inflammatory Bowel Disease Symptoms: Reliability of an Abbreviated Approach to Data Collection.

Authors:  Maria Paula Henao; Meenakshi Bewtra; Mark T Osterman; Faten N Aberra; Frank I Scott; Gary R Lichtenstein; Jennifer Kraschnewski; James D Lewis
Journal:  Inflamm Bowel Dis       Date:  2015-10       Impact factor: 5.325

8.  Use of predictive algorithms in-home monitoring of chronic obstructive pulmonary disease and asthma: A systematic review.

Authors:  Daniel Sanchez-Morillo; Miguel A Fernandez-Granero; Antonio Leon-Jimenez
Journal:  Chron Respir Dis       Date:  2016-04-20       Impact factor: 2.444

9.  Qualitative Development and Content Validity of the Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), A Patient-reported Outcome Instrument.

Authors:  Kelly P McCarrier; Thomas M Atkinson; Kendra P A DeBusk; Astra M Liepa; Michael Scanlon; Stephen Joel Coons
Journal:  Clin Ther       Date:  2016-04-01       Impact factor: 3.393

10.  Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer.

Authors:  Elisabeth M Schaffer; Ethan M Basch; Gisela M Schwab; Antonia V Bennett
Journal:  Clin Trials       Date:  2021-04-22       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.